ArticleFrontiers in neurology
Case Report: Vision-threatening manifestations of choroidal osteomas and papilloedema in presumed Camurati-Engelmann disease.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Camurati-Engelmann Disease (CED) is a rare sclerosing bone dysplasia in which skull-base hyperostosis may result in neuro-ophthalmic complications. We report a 21-year-old woman with presumed CED and known bilateral choroidal osteomas who presented with bilateral optic nerve swelling. Neuroimaging demonstrated diffuse cranial hyperostosis with optic canal narrowing but no definitive optic nerve compression or venous sinus thrombosis. Lumbar puncture confirmed raised intracranial pressure with an opening pressure of 33 cm H₂O. Optical coherence tomography revealed right eye subretinal fluid without choroidal neovascular membrane. Papilloedema improved initially with acetazolamide, but treatment was changed to oral furosemide due to intolerance to acetazolamide. There was continued visual decline in association with progressive subretinal fluid. Right eye intravitreal bevacizumab was ineffective, while fovea-sparing photodynamic therapy achieved resolution of subretinal fluid but was complicated by retinal pigment epithelial and photoreceptor loss. At 2.5-year follow-up, visual acuity was reduced in both eyes, with mild bilateral chronic papilloedema and enlargement of choroidal osteomas. This case illustrates multifactorial visual loss in CED with skull base hyperostosis arising from raised intracranial pressure and co-existing retinochoroidal pathology. This is the first documented case of CED with bilateral choroidal osteomas and highlights the role of multimodal imaging and multidisciplinary collaboration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.